

PHARMACY DOSING AND ORDERING GUIDE



FIRST AND ONLY APPROVED TREATMENT FOR PATIENTS WITH VOD

WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT

VOD=veno-occlusive disease

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

- Concomitant administration with systemic anticoagulant or fibrinolytic therapy
- Known hypersensitivity to Defitelio or to any of its excipients

**Please see additional Important Safety Information on page 7
and [click here](#) for full Prescribing Information.**

DESCRIPTION AND DOSING

Defibrotide sodium is an oligonucleotide mixture with profibrinolytic properties. The chemical name of defibrotide sodium is polydeoxyribonucleotide, sodium salt. Defibrotide sodium is a polydisperse mixture of predominantly single-stranded polydeoxyribonucleotide sodium salts derived from porcine intestinal tissue having a mean weighted molecular weight of 13–20 kDa and a potency of 27–39 and 28–38 biological units per mg as determined by 2 separate assays measuring the release of a product formed by contact between defibrotide sodium, plasmin, and a plasmin substrate.¹

Defitelio is a clear, light yellow to brown, sterile, preservative-free solution in a single-patient-use vial for intravenous use.¹

DOSING FOR DEFITELIO® (DEFIBROTIDE SODIUM)¹



Dosage

6.25 mg/kg every 6 hours (total dose 25 mg/kg/day)

Dosing based on baseline body weight prior to preparative regimen for HSCT



Administration

2-hour intravenous infusion



Days on therapy

Minimum of 21 days

Continue Defitelio until VOD resolution or up to a maximum of 60 days

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hemorrhage—Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Please see additional Important Safety Information on page 7 and [click here](#) for full Prescribing Information.

TREATMENT MODIFICATION

TREATMENT MODIFICATIONS FOR TOXICITY OR INVASIVE PROCEDURES¹

EVENT	RECOMMENDED ACTION
Hypersensitivity reaction <ul style="list-style-type: none">○ Severe or life-threatening (anaphylaxis)	<ol style="list-style-type: none">1. Discontinue Defitelio permanently; do not resume treatment.
Bleeding <ul style="list-style-type: none">○ Persistent, severe, or potentially life-threatening	<ol style="list-style-type: none">1. Withhold Defitelio.2. Treat the cause of bleeding and give supportive care as clinically indicated.3. Consider resuming treatment (at the same dose and infusion volume) when bleeding has stopped and the patient is hemodynamically stable.
<ul style="list-style-type: none">○ Recurrent significant bleeding	<ol style="list-style-type: none">1. Discontinue Defitelio permanently; do not resume treatment.
Invasive procedures	<ol style="list-style-type: none">1. There is no known reversal agent for the profibrinolytic effects of Defitelio. Discontinue Defitelio infusion at least 2 hours prior to an invasive procedure.2. Resume Defitelio treatment after the procedure, as soon as any procedure-related risk of bleeding is resolved.

Please see additional Important Safety Information on page 7 and [click here](#) for full Prescribing Information.

DEFITELIO[®]
(defibrotide sodium) injection
80 mg/mL

PREPARATION

DEFITELIO® (DEFIBROTIDE SODIUM) MUST BE DILUTED PRIOR TO INFUSION¹

Dilute Defitelio with either

- 5% Dextrose Injection, USP
- 0.9% Sodium Chloride Injection, USP

Administer the diluted solution over 2 hours.

Final concentration of Defitelio

Range of 4 mg/mL to 20 mg/mL

PREPARATION INSTRUCTIONS¹

- 1** Determine the dose (mg) and number of vials based on the individual patient's baseline weight (weight prior to the preparative regimen for HSCT).
- 2** Calculate the volume of Defitelio needed, withdraw this amount from the vial(s), and add it to the infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection for each dose to make a final concentration of 4 mg/mL to 20 mg/mL.
- 3** Gently mix the solution for infusion.
- 4** Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Only clear solutions without visible particles should be used. Depending on the type and amount of diluent, the color of the diluted solution may vary from colorless to light yellow.

Storage and handling¹

- Supplied in a single-patient-use, clear glass vial
- Vials contain no antimicrobial preservatives
- Up to 4 doses may be prepared at one time, if refrigerated
- Use the diluted Defitelio solution within 4 hours if stored at room temperature or within 24 hours if stored under refrigeration
- Partially used vials should be discarded
- Store unused vials at 20°C–25°C (68°F–77°F)

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Hypersensitivity Reactions—Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Please see additional Important Safety Information on page 7 and [click here](#) for full Prescribing Information.

HOW DEFITELIO IS SUPPLIED



Defitelio is supplied in a single-patient-use, clear glass vial.¹

PACKAGING INFORMATION

Vial volume	2.5 mL vial (200 mg defibrotide sodium)
Carton quantity	10 vials
Carton dimensions (L x W x H)	3-33/64" x 1-43/64" x 1-27/32"

Consider that patients receiving Defitelio should be treated for a minimum of 21 days or until VOD resolution, up to a maximum of 60 days.¹

NDC INFORMATION¹

Billing	Single vial: 200 mg/2.5 mL (concentration of 80 mg/mL) NDC 68727-800-01
Ordering	Carton: (10 vials) NDC 68727-800-02

NDC=National Drug Code

IMPORTANT SAFETY INFORMATION

Most Common Adverse Reactions

The most common adverse reactions (incidence $\geq 10\%$ and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see additional Important Safety Information on page 7 and [click here](#) for full Prescribing Information.

DEFITELIO[®]
(defibrotide sodium) injection
80 mg/mL

HOW TO ORDER DEFITELIO® (DEFIBROTIDE SODIUM)

Order through McKesson Plasma and Biologics

Online:

<http://connect.mckesson.com>

Phone:

1-877-625-2566

Fax:

1-888-752-7626

Email:

MPBOrders@mckesson.com

Email for all other information requests:

MPB@mckesson.com

- Orders can be placed Monday through Friday, 9 AM to 7:30 PM ET
 - Overnight delivery is available for orders placed by 7:30 PM ET
 - For emergency orders after hours of service, call 1-877-625-2566 (24/7/365)
- Verify your institution has a contract with McKesson Plasma and Biologics before ordering; if not, contact McKesson Plasma and Biologics or your Jazz Strategic Account Manager (SAM) in your territory for information about setting up an account

Based on the potential for rapid progression of VOD, it is advisable to have enough product on hand to treat an average-size patient for up to 48 hours.



JUMPSTART™

The JumpStart Program at Jazz Pharmaceuticals provides information about coverage and reimbursement. Specialists are available to answer your questions. For additional questions regarding reimbursement, contact your Jazz SAM in your territory.

**Contact our JumpStart Specialists at 1-888-837-4397,
Monday through Friday, 9 AM to 6 PM ET.**

**Please see additional Important Safety Information on page 7
and [click here](#) for full Prescribing Information.**

IMPORTANT SAFETY INFORMATION



Contraindications

Defitelio is contraindicated in the following conditions:

- Concomitant administration with systemic anticoagulant or fibrinolytic therapy
- Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence $\geq 10\%$ and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please [click here](#) for full Prescribing Information.

For additional information, visit defitelio.com or call Jazz Pharmaceuticals Customer Service at 1-800-833-3533.

Reference: 1. Defitelio [package insert]. Palo Alto, CA: Jazz Pharmaceuticals.



Jazz Pharmaceuticals®

©2016 Jazz Pharmaceuticals DEF-0006a(1) Rev0916